Cargando…

Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells

Human epidermal growth factor receptor 2 (HER2) is one of the most studied tumor-associated antigens for cancer immunotherapy. An engineered anti-HER-2 chimeric A21 antibody (chA21) is a chimeric antibody targeted to subdomain I of the HER2 extracellular domain. Here, we report the anti-tumor activi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ruilin, Hu, Siyi, Chang, Yan, Zhang, Zhihui, Zha, Zhao, Huang, Hui, Shen, Guodong, Liu, Jing, Song, Lihua, Wei, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849019/ https://www.ncbi.nlm.nih.gov/pubmed/27092488 http://dx.doi.org/10.3390/ijms17040563

Ejemplares similares

Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma
por: Ciprotti, Marika, et al.
Publicado: (2014)

Anti-Hu antibodies activate enteric and sensory neurons
por: Li, Qin, et al.
Publicado: (2016)

Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft
por: Zhang, Anli, et al.
Publicado: (2010)

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers
por: Okita, Kouki, et al.
Publicado: (2020)

A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
por: Wu, Xiaoqiong, et al.
Publicado: (2018)

Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures
por: Greenlee, John E, et al.
Publicado: (2014)

Paraneoplastic neurological syndrome with positive anti-Hu and anti-Yo antibodies: A case report
por: Li, Zi-Chao, et al.
Publicado: (2022)

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
por: Mohammadi, Mehdi, et al.
Publicado: (2021)

Xin hua jing /
Publicado: (1982)

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer
por: Huemer, Florian, et al.
Publicado: (2015)

Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors
por: Farina, Antonio, et al.
Publicado: (2022)

Broad Anti-Viral Capacities of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-Gan Granule and Rational use Against COVID-19 Based on Literature Mining
por: Shi, Mingfei, et al.
Publicado: (2021)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

Anti-Hu-related epilepsy diagnosed after surgical management
por: Zheng, Yongsu, et al.
Publicado: (2020)

Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis
por: Schwenkenbecher, Philipp, et al.
Publicado: (2016)

HUA ENHANCER1 Mediates Ovule Development
por: Wei, Shuai-Jie, et al.
Publicado: (2020)

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice
por: Ladjemi, Maha Z, et al.
Publicado: (2011)

JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGATE, EXHIBITS POTENT ANTITUMOR EFFICACY
por: Wang, Pilin, et al.
Publicado: (2023)

Conformational characterization of a novel anti-HER2 candidate antibody
por: Moro Pérez, Leina, et al.
Publicado: (2019)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Bound-state solutions and thermal properties of the modified Tietz–Hua potential
por: Onate, C. A., et al.
Publicado: (2021)

Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis
por: Villagrán-García, Macarena, et al.
Publicado: (2023)

Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
por: Huang, Sijia, et al.
Publicado: (2018)

A Case of Paraneoplastic Neurological Syndrome Expressing Dual Antineuronal Antibodies: Anti-Hu and Recoverin
por: Ryu, Ho-Sung, et al.
Publicado: (2020)

First person – Jiang-Hua Liu
Publicado: (2020)

Virus-like particle display of HER2 induces potent anti-cancer responses
por: Palladini, Arianna, et al.
Publicado: (2018)

Paraneoplastic Confusion: A Case of Anti-Hu Encephalitis
por: Drekolias, Dimitrios, et al.
Publicado: (2020)

Cationic Amphipathic Triazines with Potent Anti-bacterial, Anti-inflammatory and Anti-atopic Dermatitis Properties
por: Gunasekaran, Pethaiah, et al.
Publicado: (2019)

Paraneoplastic Focal Outer Retinitis and Optic Neuropathy in a Patient with Small Cell Lung Carcinoma and Anti-CRMP5, Anti-HU and Anti-Amphiphysin Antibodies
por: Martínez-Rubio, Clara, et al.
Publicado: (2020)

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
por: Liu, Jiayu, et al.
Publicado: (2019)

Rare Association of Anti-Hu Antibody Positive Paraneoplastic Neurological Syndrome and Transitional Cell Bladder Carcinoma
por: Lukacs, S., et al.
Publicado: (2012)

Repositioning linifanib as a potent anti-necroptosis agent for sepsis
por: Yu, Liang, et al.
Publicado: (2023)

Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer
por: Wu, Feng-Lei, et al.
Publicado: (2017)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies
por: Hollevoet, Kevin, et al.
Publicado: (2018)

Facial pain as first manifestation of anti-Hu paraneoplastic syndrome
por: Demarquay, Geneviève, et al.
Publicado: (2010)

Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells
por: Zhang, AnLi, et al.
Publicado: (2010)

International Symposium in Memory of Hua Loo Keng
por: Gong, Sheng, et al.
Publicado: (1991)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma
por: Ehrlich, Debra, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r7r7fmi65qhg159oc5dffas0br